Peptide Samples
Peptide Samples is reader-supported. Our editors verify every clinic here — affiliate commissions fund the work, they don't pick the winners. Full disclosure

Medical Disclaimer

Information on Peptide Samples is provided for general educational and editorial purposes. It is not medical advice. It is not a substitute for consultation with a licensed healthcare provider. We do not establish a clinician-patient relationship through this site.

Peptide therapy requires a clinical evaluation

Most peptide therapies discussed on this site are prescription-only. They require a clinical evaluation by a licensed prescribing clinician — typically including a baseline lab panel appropriate to the protocol — and ongoing monitoring. Self-administration of peptides obtained outside the legal compounding framework is dangerous and exposes patients to product-quality, sterility, and dosing risks the published literature does not characterize.

No dosing protocols on this site

We do not publish dosing protocols for any peptide we cover. The April 2026 FDA enforcement action against 7 peptide research-use-only vendor sites clarified that publishing dosing-implication content is the line that triggers drug-misbranding enforcement. Specific dosing for prescription peptides is determined by your prescribing clinician based on your labs, indication, and goals.

FDA Cat-2 / research-only peptides

Several peptides we cover (BPC-157, TB-500, melanotan-2, and others) are on the FDA Category 2 bulk substances list, prohibiting them from 503A compounding. These molecules have NO legitimate US clinical channel as of this page. We publish educational pages about them for context only and do NOT link to research-chemical vendors regardless of their RUO disclaimers. If you are interested in indications these molecules are researched for, talk to a peptide-friendly clinician about legitimate alternatives.

Side effects and contraindications

Different peptides have different side-effect profiles and contraindications. Common across the GHRH/GHRP class: relative contraindication in active malignancy (GH stimulation has theoretical IGF-1 implications), pregnancy and breastfeeding, untreated diabetic retinopathy. Tesamorelin can worsen glucose intolerance; PT-141 can transiently elevate blood pressure; thymosin alpha-1 is not appropriate for patients with active autoimmune disease without specialist oversight. The per-medication pages contain medication-specific safety information; nothing on this site substitutes for clinical evaluation.

Emergency situations

Seek emergency medical attention if you experience severe allergic reaction, sudden vision changes, chest pain, or signs of an acute adverse drug reaction following any peptide injection.